JP Morgan Chase
TOVX icon

JP Morgan Chase’s Theriva Biologics TOVX Stock Holding History

JP Morgan Chase’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed -$8 – 7872
2023
Q3 		$8 Buy
+1
New +$15 ﹤0.01% 7320
2017
Q2 		– Sell
-7
Closed -$38K – 5218
2017
Q1 		$38K Buy
+7
New +$48.8K ﹤0.01% 4594
2015
Q2 		– Sell
-1
Closed -$23K – 4178
2015
Q1 		$23K Buy
+1
New +$17.9K ﹤0.01% 3981

Other funds holding TOVX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase's TOVX Position: Q4 2023 in Review

JP Morgan Chase sold out of Theriva Biologics (TOVX) in Q4 2023, closing a stake of 1 share — an estimated $8 sold.

JP Morgan Chase first reported a position in TOVX in Q1 2015 and held it in 3 quarters. The position peaked at $38K in Q1 2017. 20 funds tracked by Wall St. Rank hold TOVX as of Q4 2023.

  • JP Morgan Chase reported no remaining Theriva Biologics position as of Q4 2023 after selling out during the quarter.
  • JP Morgan Chase sold 1 Theriva Biologics share in Q4 2023, an estimated $8.
  • JP Morgan Chase first reported a position in Theriva Biologics in Q1 2015 and held it in 3 quarters.
  • JP Morgan Chase's Theriva Biologics position peaked at $38K in Q1 2017.
  • 20 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.